0001445815
false
0001445815
2022-05-12
2022-05-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 12, 2022
BIOXYTRAN,
INC.
(Exact
Name if Business Issuer as specified in its Charter)
| Nevada |
|
001-35027 |
|
26-2797630 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File
Number) |
|
(IRS Employer
Identification Number) |
75,
Second Avenue,
Suite 605
Needham MA, 02494
(Address
of principal executive offices, including zip code)
(617)
494-1199
(Registrant’s
telephone number including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
| |
☐ |
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) |
| |
☐ |
Soliciting material pursuant to Rule 1 4a- 12
under the Exchange Act (17 CFR 240.1 4a- 12) |
| |
☐ |
Pre-commencement communications pursuant to
Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b)) |
| |
☐ |
Pre-commencement communications pursuant to
Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| |
|
|
|
|
| Common Stock, par value $0.001 |
|
BIXT |
|
OTC Pink |
Item
8.01 Other Events.
On
May 12th, 2022, the International Bureau of the Patent Cooperation Treaty (PCT) approved and published two patent applications
from Bioxytran, Inc.:
| ● | WO
2022/099061 - Polysaccharides for Use in Treating Sars-Cov-2 Infections - The invention
provides a method for treating SARS-CoV-2 by administering an effective amount of galactomannans
to a subject in need thereof. |
| ● | WO2022/099061
- Polysaccharides for IV Administration that Treat Sars-Cov-2 Infections - The invention
provides a method for treating SARS-CoV-2 by administering an effective amount of pectin
polysaccharides to a subject in need thereof. |
On
June 8, 2022 United States Patent and Trademark Office (USPTO) approved the Trademark ProLectin to be published in the published
in the Trademark Official Gazette (TMOG) on June 28, 2022.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| |
By: |
/s/
David Platt |
| |
Name: |
Dr. David Platt |
| |
Title: |
President and Chief Executive Officer |
| |
|
| |
Dated:
June 10, 2022 |
Exhibit 10.69
PATENT
COOPERATION TREATY WO 2022/099052 PCT/US2021/058310 From the INTERNATIONAL BUREAU PCT To:
NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION MCDONALD,
J. Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D’AMERIQUE
Date of mailing (day/month/year) 12 May 2022 (12.05.2022) Applicant’s or agent’s
file reference 51577-002WO2 IMPORTANT NOTICE International application No. PCT/US2021/058310
International filing date (day/month/year) 05 November 2021 (05.11.2021) Priority date (day/month/year)
06 November 2020 (06.11.2020) Applicant BIOXYTRAN, INC. The applicant is hereby notified that
the International Bureau: ☒ has published the above-indicated international application
on 12 May 2022 (12.05.2022) under No. WO 2022/099052 □ has republished the above-indicated
international application on under No. WO For an explanation as to the reason for this republication
of the international application, reference is made to INID codes (15), (48) or (88) (as the case
may be) on the front page of the published international application. - A copy of the international
application is available for viewing and downloading on WIPO’s website at the following address:
https://patentscope.wipo.int/ (in the appropriate field of the structured search, enter the PCT or
WO number). - The applicant may also obtain a paper copy of the published international application
from the International Bureau by sending an e-mail to patentscope@wipo.int or by submitting a written
request to the contact details provided below. Warning: Following publication of the international
application, applicants, agents and inventors may receive misleading requests for payment of fees
that appear to come from the International Bureau of WIPO or other patent Offices which are unrelated
to the processing of international applications under the PCT. Agents are particularly encouraged
to be vigilant and alert their clients about this practice. Examples of such requests for payment
which have been received by the International Bureau can be found at: http://www.wipo.int/pct/en/waming/pct_warning.htm.
Please forward copies of any such requests to pct.legal@wipo.int. The International Bureau of WIPO
34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer Xin Wang e-mail pct.team2@wipo.int
Telephone No. +41 22 338 74 02 FormPCT/IB/311 (revised January 2020) |
Exhibit 10.70
WO
2022/099061 PCT/US2021/058321 PATENT COOPERATION TREATY From the INTERNATIONAL BUREAU PCT NOTIFICATION
CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION To: MCDONALD,
J., Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D’AMERIQUE Date
of mailing (day/month/year)
12 May 2022 (12.05.2022) Applicant’s or agent’s
file reference 51577-003W02 IMPORTANT NOTICE International
application No. PCT/US2021/058321
International filing date (day/month/year)
05 November 2021 (05.11.2021) Priority date (day/month/year)
06 November 2020 (06.11.2020) Applicant
BIOXYTRAN, INC. The applicant is hereby notified that the International Bureau:
has published the above-indicated international application on 12 May 2022 (12.05.2022)
under No. WO 2022/099061 □ has republished the above-indicated international
application on under No. WO For an explanation as to the reason for this republication of the international application, reference
is made to INID codes (15), (48) or (88) (as the case may be)
on the front page of the published international application. - A copy of the international application is available for viewing
and downloading on WIPO’s website at the following address: https://patentscope.wipo.int/ (in the appropriate field of the
structured search, enter the PCT or WO number). - The applicant may also obtain a paper copy of the published international application
from the International Bureau by sending an e-mail to patentscope@wipo.int or by submitting a written request to the contact details
provided below. Warning: Following publication of the international application,
applicants, agents and inventors may receive misleading requests for payment of fees that appear to come from the International
Bureau of WIPO or other patent Offices which are unrelated to the processing of international applications under the PCT. Agents
are particularly encouraged to be vigilant and alert their clients about this practice. Examples of such requests for payment
which have been received by the International Bureau can be found at: http://www.wipo.int/pct/en/waming/pct_warning.htm. Please
forward copies of any such requests to pct.legal@wipo.int. The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva
20, Switzerland Authorized officer Xiaofan Tang e-mail pct.team2@wipo.int Telephone No. +41 22 338 74 02 Form PCT/IB/311 (revised
January 2020)
Exhibit 10.71
 |
UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) |
Commissioner for Trademarks
www.uspto.gov
OFFICIAL USPTO NOTICE OF PUBLICATION UNDER 12(a)
U.S. Application Serial No. 90888912
Mark: PROLECTIN
International Class(es): 005
Owner: Pharmalectin, Inc.
Docket/Reference No. 51577-T02001
Issue Date: June 8, 2022
Your mark is scheduled to publish in the Trademark Official
Gazette (TMOG) on June 28, 2022.
Your mark appears to be entitled to register on the Principal
Register upon the acceptance of a statement of use, subject to any claims of concurrent use.
What happens when your mark publishes. Within 30 days
of the publication date, any party who believes it will be damaged by the registration of the mark may file a notice of opposition
(or extension of time) with the Trademark Trial and Appeal Board. If no objection is filed, we will issue a Notice of allowance.
View your mark in the TMOG after the publication date
at https://tmog.uspto.gov/ by selecting your publication date in the “issues” field, entering your serial
number in the “search by” field, and clicking on the magnifying glass.
Ensure that the information in the TMOG is correct. If
any information is incorrect, promptly request correction using the “Post-Approval/Publication/Post-Notice of Allowance (NOA)
Amendment” form at https://teas.uspto.gov/office/ppa/. For more information, see https://www.uspto.gov/trademark/trademark-updates-andannouncements/procedures-submitting-amendmentscorrections-trademark.
Direct questions about this notice to the Trademark Assistance
Center (TAC)at 1-800-786-9199 (select option 1) or TrademarkAssistanceCenter@uspto.gov.
Email Address(es):
cedocket@clarkelbing.com